TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2192462

Group type: EXPERIMENTAL
Intervention: Daily injections of growth hormone (0.3 mg/kg weekly)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Three times weekly injections of growth hormone (0.3 mg/kg weekly)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Once a week injections of growth hormone (0.3 mg/kg weekly)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Daily injections of growth hormone (after switching from once or three times a week)
Number of subjects: 47
Study: 336453

Group type: EXPERIMENTAL
Intervention: Carbenoxolone sodium
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 31251094

Group type: EXPERIMENTAL
Intervention: Mepolizumab 75 mg intravenously (MENSA)
Number of subjects: 1755

Group type: EXPERIMENTAL
Intervention: Mepolizumab 100 mg subcutaneously (MUSCA)
Number of subjects: 1755

Group type: COMPARATOR
Intervention: Historical exacerbations
Number of subjects: 1755

Group type: COMPARATOR
Intervention: Within-study severe exacerbations (MENSA)
Number of subjects: 1755

Group type: COMPARATOR
Intervention: Within-study severe exacerbations (MUSCA)
Number of subjects: 1755
Study: 30656873

Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (traditional training)
Number of subjects: 0
Study: 28698994

Group type: EXPERIMENTAL
Intervention: Tolvaptan
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Sodium dipping group (n = 100; 54.3%)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Sodium dipping group
Number of subjects: 184
Study: 25743173

Group type: EXPERIMENTAL
Intervention: Anacetrapib 100 mg
Number of subjects: 306

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Anacetrapib
Number of subjects: 306
Study: 24613523

Group type: EXPERIMENTAL
Intervention: BioThrax® (anthrax vaccine adsorbed) administered subcutaneously (SC) in a three-dose regimen (0, 2, and 4 weeks)
Number of subjects: 200
Study: 22980315

Group type: EXPERIMENTAL
Intervention: Bitopertin 30 mg
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Bitopertin 175 mg
Number of subjects: 169

Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg
Number of subjects: 169

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 169
Study: 19709418

Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 841

Group type: EXPERIMENTAL
Intervention: Chlorproguanil-dapsone (CPD)
Number of subjects: 841

Group type: COMPARATOR
Intervention: Sulphadoxine-pyrimethamine (SP)
Number of subjects: 841
Study: 17599875

Group type: EXPERIMENTAL
Intervention: Off-pump CABG
Number of subjects: 57

Group type: COMPARATOR
Intervention: On-pump CABG
Number of subjects: 57
Study: 15226466

Group type: EXPERIMENTAL
Intervention: Isoflavones from red clover-derived dietary supplement (43.5 mg/d)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 205
Study: 12206944

Group type: COMPARATOR
Intervention: Ankle braces
Number of subjects: 24
Study: 9523247

Group type: EXPERIMENTAL
Intervention: Styrene exposure (high-level exposure)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control (unexposed subjects)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Low-level exposure (MA + PGA < or = 159 mg/g creatinine)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: High-level exposure (MA + PGA > 159 mg/g creatinine)
Number of subjects: 22
Study: 8595636

Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil suspension 30 mg/kg per day in two divided doses (n = 235)
Number of subjects: 477

Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate suspension 40 mg/kg per day in three divided doses (n = 242)
Number of subjects: 477

Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil suspension (bacteriologically assessable patients)
Number of subjects: 477

Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate suspension (bacteriologically assessable patients)
Number of subjects: 477

Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil suspension
Number of subjects: 477

Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate suspension
Number of subjects: 477
Study: 2597656

Group type: EXPERIMENTAL
Intervention: Preservation of the posterior branch of the great auricular nerve
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sacrifice of the posterior branch of the great auricular nerve
Number of subjects: 12
Study: 6107157

Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 8

Group type: COMPARATOR
Intervention: Ranitidine
Number of subjects: 8
Study: 30451342

Group type: EXPERIMENTAL
Intervention: Nitrofurazone-coated silicone urinary catheter
Number of subjects: 214

Group type: COMPARATOR
Intervention: Non-impregnated silicone urinary catheter
Number of subjects: 214
Study: 28249980

Group type: EXPERIMENTAL
Intervention: Operative treatment
Number of subjects: 176

Group type: COMPARATOR
Intervention: Non-operative treatment
Number of subjects: 176
Study: 25851433

Group type: EXPERIMENTAL
Intervention: Glycine powder air-polishing (GPAP)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Ultrasonic (US) debridement
Number of subjects: 37
Study: 24730013

Group type: EXPERIMENTAL
Intervention: BIS visible (BIS value shown throughout the procedure)
Number of subjects: 0

Group type: COMPARATOR
Intervention: BIS not visible (BIS hidden, monitoring based on clinical signs and expiratory fraction of halogenated anesthetic agents)
Number of subjects: 0
Study: 23189308

Group type: COMPARATOR
Intervention: PAB (autogenous particulated bone)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: PAB + beta‐tricalcium phosphate (Β‐TCP)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: PAB + beta‐tricalcium phosphate (Β‐TCP) + hydroxyapatite (HA)
Number of subjects: 30
Study: 20451774

Group type: EXPERIMENTAL
Intervention: First Class Appliance (FCA)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control (untreated group)
Number of subjects: 26
Study: 18625674

Group type: EXPERIMENTAL
Intervention: Cylinder oxygen
Number of subjects: 20

Group type: COMPARATOR
Intervention: Cylinder air
Number of subjects: 20
Study: 16203934

Group type: EXPERIMENTAL
Intervention: MCV-4
Number of subjects: 881

Group type: COMPARATOR
Intervention: PSV-4
Number of subjects: 881
Study: 12236607

Group type: EXPERIMENTAL
Intervention: Novel sleep aid
Number of subjects: 80
Study: 10090538

Group type: COMPARATOR
Intervention: Formula-fed infants
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Breastfed infants
Number of subjects: 100
Study: 7811176

Group type: EXPERIMENTAL
Intervention: Metaproterenol (80 mg/day)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 2349369

Group type: EXPERIMENTAL
Intervention: Caffeine (single dose equivalent to two to four cups of coffee)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7273596

Group type: EXPERIMENTAL
Intervention: 0.1 mg brotizolam
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 0.3 mg brotizolam
Number of subjects: 11

Group type: COMPARATOR
Intervention: 10 mg flurazepam
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 31067587

Group type: EXPERIMENTAL
Intervention: Physical therapy by PTs with varying experience (2 to 21 years)
Number of subjects: 79
Study: 31449992

Group type: EXPERIMENTAL
Intervention: Microelectrode recording (MER)
Number of subjects: 273

Group type: COMPARATOR
Intervention: Control (initial anatomic target, AT)
Number of subjects: 273
Study: 28657870

Group type: EXPERIMENTAL
Intervention: Clindamycin
Number of subjects: 786

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (TMP-SMX)
Number of subjects: 786

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 786

Group type: EXPERIMENTAL
Intervention: TMP-SMX
Number of subjects: 786
Study: 26201184

Group type: EXPERIMENTAL
Intervention: UPPP oriented surgery in cognitive dysfunction group
Number of subjects: 44

Group type: COMPARATOR
Intervention: Normal control group
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Cognitive dysfunction group
Number of subjects: 44

Group type: COMPARATOR
Intervention: Cognitively normal group
Number of subjects: 44
Study: 23116051

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Prescribed Advice (PA)
Number of subjects: 30
Study: 21409383

Group type: EXPERIMENTAL
Intervention: XELOX + BV
Number of subjects: 64

Group type: COMPARATOR
Intervention: FOLFOX-4 + BV
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Both XELOX + BV and FOLFOX-4 + BV
Number of subjects: 64
Study: 19288942

Group type: EXPERIMENTAL
Intervention: Rhomboid excision and Limberg flap (group B)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Open excision and secondary healing (group A)
Number of subjects: 49
Study: 17614893

Group type: EXPERIMENTAL
Intervention: Combination of didactic guidelines and netiquette advice
Number of subjects: 112

Group type: COMPARATOR
Intervention: Netiquette advice only
Number of subjects: 112

Group type: COMPARATOR
Intervention: Trivial information guidelines
Number of subjects: 112
Study: 14984379

Group type: EXPERIMENTAL
Intervention: Lamivudine discontinued
Number of subjects: 34
Study: 11351930

Group type: EXPERIMENTAL
Intervention: Intramuscular buprenorphine/naloxone (1/0.25, 2/0.5, 4/1, 8/2, 16/4 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Sublingual buprenorphine/naloxone (1/0.25, 2/0.5, 4/1, 8/2, 16/4 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Intramuscular hydromorphone (10 mg) and naloxone (0.25 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Intramuscular buprenorphine alone (8 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Sublingual buprenorphine alone (8 mg)
Number of subjects: 8
Study: 9135734

Group type: EXPERIMENTAL
Intervention: pCMV‐CFTR:2.4 mg DOTAP (400 micrograms)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Buffer only (control)
Number of subjects: 16
Study: 8198341

Group type: EXPERIMENTAL
Intervention: HA-1A
Number of subjects: 621

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 621
Study: 2823594

Group type: EXPERIMENTAL
Intervention: Psyllium gum
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Combination of psyllium gum and wheat bran
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Wheat bran
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (4 g/d fiber)
Number of subjects: 12
Study: 31923556

Group type: EXPERIMENTAL
Intervention: Spiritual care interventions
Number of subjects: 19

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 19
Study: 29859267

Group type: EXPERIMENTAL
Intervention: TeleCAM (home-based telerehabilitation intervention using pre-loaded tablets and IVR system technology)
Number of subjects: 820

Group type: COMPARATOR
Intervention: DirectCAM (clinic-based intervention delivered by a therapist)
Number of subjects: 820
Study: 27662565

Group type: EXPERIMENTAL
Intervention: Daily sedation interruption + protocolized sedation
Number of subjects: 64

Group type: COMPARATOR
Intervention: Protocolized sedation only
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Daily sedation interruption + protocolized sedation (for children > 4 years old)
Number of subjects: 64
Study: 25693004

Group type: EXPERIMENTAL
Intervention: Allisartan Isoproxil 240mg
Number of subjects: 275

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 275
Study: 22288788

Group type: EXPERIMENTAL
Intervention: Statin therapy group (n = 14)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (n = 14)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Both groups after eccentric exercise
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Both groups after second eccentric exercise bout
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 28
Study: 22402092

Group type: EXPERIMENTAL
Intervention: Inpatient treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Day hospital treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ISE measures
Number of subjects: 0
Study: 17697398

Group type: EXPERIMENTAL
Intervention: 5 g short-chain fructo-oligosaccharides (sc-FOS) per day for 6 weeks
Number of subjects: 105

Group type: COMPARATOR
Intervention: 5 g placebo (sucrose and maltodextrins) per day for 6 weeks
Number of subjects: 105
Study: 16302654

Group type: EXPERIMENTAL
Intervention: Defunctioning colostomy
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Hartmann procedure
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Diverting colostomy
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Postoperative morbidity
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Postoperative mortality
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Anastomotic leak
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Reintervention
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Major stoma related complications
Number of subjects: 104
Study: 11840286

Group type: EXPERIMENTAL
Intervention: GSTT1(+)
Number of subjects: 193

Group type: COMPARATOR
Intervention: GSTT1(-)
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: GSTT1(+) and GSTT1(-)
Number of subjects: 193
Study: 10635157

Group type: EXPERIMENTAL
Intervention: Mini-transitional implants (MTIs) placed medially to the permanent implants.
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: MTI-supported dentures
Number of subjects: 12
Study: 8544287

Group type: EXPERIMENTAL
Intervention: Sevoflurane 1.0 % in oxygen (O2)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Sevoflurane 1.0 % with 67 % N2O in O2
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Sevoflurane 1.7 % in O2
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Sevoflurane 0.7 % with 67 % N2O in O2
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Intravenous administration of fentanyl and midazolam with 67 % N2O
Number of subjects: 31

Group type: COMPARATOR
Intervention: Intravenous administration of fentanyl and midazolam without N2O
Number of subjects: 31
Study: 1673645

Group type: EXPERIMENTAL
Intervention: Esmolol 100 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Esmolol 200 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 7083512

Group type: EXPERIMENTAL
Intervention: Diltiazem 120 mg
Number of subjects: 12
Study: 31727641

Group type: EXPERIMENTAL
Intervention: High user ratings (4, 5 stars)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Low user ratings (1, 2, 3 stars)
Number of subjects: 400

Group type: COMPARATOR
Intervention: App store (iTunes vs Google Play)
Number of subjects: 400
Study: 28401617

Group type: EXPERIMENTAL
Intervention: Crisis resource management principles and team debriefing in simulation training
Number of subjects: 116

Group type: COMPARATOR
Intervention: Control group (only simulation training)
Number of subjects: 116
Study: 27579634

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate plus salmeterol
Number of subjects: 6208

Group type: COMPARATOR
Intervention: Fluticasone propionate alone
Number of subjects: 6208
Study: 24119775

Group type: EXPERIMENTAL
Intervention: Treadmill training for 2 weeks with increasing velocity
Number of subjects: 23
Study: 22664648

Group type: EXPERIMENTAL
Intervention: Medtable™ EMR-integrated tool for medication management
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care control condition
Number of subjects: 0
Study: 19598056

Group type: EXPERIMENTAL
Intervention: Implementation intention condition
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 35
Study: 16433927

Group type: EXPERIMENTAL
Intervention: Health promotion intervention over 6 months
Number of subjects: 1013

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1013

Group type: EXPERIMENTAL
Intervention: Health promotion intervention
Number of subjects: 1013
Study: 14583064

Group type: EXPERIMENTAL
Intervention: Sibutramine (10-20 mg daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sibutramine
Number of subjects: 0
Study: 10839660

Group type: EXPERIMENTAL
Intervention: Multivitamins
Number of subjects: 1083

Group type: COMPARATOR
Intervention: No multivitamins
Number of subjects: 1083

Group type: EXPERIMENTAL
Intervention: Vitamin A
Number of subjects: 1083

Group type: COMPARATOR
Intervention: No vitamin A
Number of subjects: 1083
Study: 8985799

Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation (CR) programs after myocardial infarction (MI)
Number of subjects: 2740

Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation (CR) programs after coronary angioplasty (PTCA)
Number of subjects: 2740

Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation (CR) programs after coronary artery bypass surgery (CABS)
Number of subjects: 2740

Group type: COMPARATOR
Intervention: Post-MI women enrollment in CR programs
Number of subjects: 2740

Group type: COMPARATOR
Intervention: Post-CABS women enrollment in CR programs
Number of subjects: 2740
Study: 1284156

Group type: EXPERIMENTAL
Intervention: Gallopamil (50 mg t.i.d. for 4 weeks)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 6377491

Group type: EXPERIMENTAL
Intervention: Orgotein 16 mg
Number of subjects: 36

Group type: COMPARATOR
Intervention: Methylprednisolone acetate 40 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Orgotein 8 mg
Number of subjects: 36
Study: 31115688

Group type: EXPERIMENTAL
Intervention: Dexamethasone-bupivacaine
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 120
Study: 30081380

Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg ketamine infusion
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg ketamine infusion
Number of subjects: 71

Group type: COMPARATOR
Intervention: Normal saline infusion
Number of subjects: 71
Study: 26695494

Group type: EXPERIMENTAL
Intervention: Psychotropic medications
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Nonpsychotropic medications
Number of subjects: 88
Study: 24913351

Group type: EXPERIMENTAL
Intervention: Exercise intervention (30 min at moderate intensity on a bicycle ergometer)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 30
Study: 22885073

Group type: EXPERIMENTAL
Intervention: Previews of the surrounding environment given prior to some trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Egocentric frame of reference
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Spatial memory derived from vision or spatial language
Number of subjects: 0
Study: 21308265

Group type: EXPERIMENTAL
Intervention: Piper methysticum
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Matricaria recutita
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard anxiolytics (benzodiazepines, buspirone, antidepressants)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Galphimia glauca, Passiflora incarnata, Valeriana officinalis
Number of subjects: 0
Study: 17267292

Group type: EXPERIMENTAL
Intervention: 5.25 mg midazolam
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 1.75 mg midazolam
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 16060741

Group type: EXPERIMENTAL
Intervention: Abstractly worded messages
Number of subjects: 0

Group type: COMPARATOR
Intervention: Concretely worded messages
Number of subjects: 0
Study: 12378657

Group type: EXPERIMENTAL
Intervention: Crystalloid intravenous fluid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Colloid intravenous fluid
Number of subjects: 0
Study: 9988284

Group type: EXPERIMENTAL
Intervention: ACE inhibitors for left ventricular dysfunction (LVD) and/or diabetes mellitus (DM)
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: Aspirin for history of myocardial infarction (MI)
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: Warfarin for chronic atrial fibrillation (AF)
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: Any or all indicated medications
Number of subjects: 407
Study: 7763057

Group type: EXPERIMENTAL
Intervention: Cryopreserved embryos
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control (normal conception)
Number of subjects: 91
Study: 1967677

Group type: EXPERIMENTAL
Intervention: Intramuscular hydrocortisone (200 mg)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Rectal hydrocortisone (200 mg)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control (healthy subjects)
Number of subjects: 25
Study: 7375869

Group type: EXPERIMENTAL
Intervention: Biarison (600-900 mg daily)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Indomethacin (50-100 mg daily)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Biarison (used in treatment of active SLE)
Number of subjects: 55
Study: 30461337

Group type: EXPERIMENTAL
Intervention: Dienogest 2 mg once daily
Number of subjects: 220
Study: 26989845

Group type: EXPERIMENTAL
Intervention: Proximal frame (intervention to reduce psychological distance)
Number of subjects: 333

Group type: COMPARATOR
Intervention: Distal frame (control to increase psychological distance)
Number of subjects: 333
Study: 25464263

Group type: EXPERIMENTAL
Intervention: Three lead ECG screening
Number of subjects: 1003
Study: 22925993

Group type: EXPERIMENTAL
Intervention: Auscultation
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Palpation
Number of subjects: 64

Group type: COMPARATOR
Intervention: Overall assessment
Number of subjects: 64
Study: 20204674

Group type: EXPERIMENTAL
Intervention: Raltitrexed (3 mg/m² i.v. every 21 days) plus gefitinib (250 mg p.o. daily)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Raltitrexed (3 mg/m² i.v. every 21 days)
Number of subjects: 76
Study: 18809275

Group type: EXPERIMENTAL
Intervention: L-carnitine (0.5 g/day for two days, followed by 1g/day for two days, and then 2g/day for 10 days)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: L-carnitine (during exploratory analysis)
Number of subjects: 29
Study: 16445340

Group type: EXPERIMENTAL
Intervention: Single-task balance training
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Dual-task training under a fixed-priority instructional set
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Dual-task training under a variable-priority instructional set
Number of subjects: 3